Ronald Realubit

Ronald Realubit

Titles

Associate Director of Operations, Columbia Genome Center

Phone

(212) 851-4749

Ronald Realubit is the Associate Director of Operations at the Columbia Genome Center and he has specialized skills, training, and education for developing a system that ensures timely and efficient execution of experiments and sharing of information and knowledge. His work is driven by a strong belief that real value comes from participating in effective collaborations that are supported by tailored information management systems, as experienced firsthand at Rockefeller University and a start-up biotech company, Therasis. He manages operations of innovative research methods at the Columbia Genome Center and also designs, develops, and implements a knowledge strategy that maximizes efficient use of available resources and involves all team members for carrying out a unified effort to deliver quality data.


Education History

MS, Columbia University
Information and Knowledge Strategy

BS, Montclair State University
Science Informatics with concentration in Molecular Biology


Publications

Latif R, Realubit R, Karan C, Mezei M, Davies TF. TSH receptor signaling abrogation by a novel small molecule. Front Endocrinol (Lausanne). 2016 Sep 27;7:130.

Chang JB, Quinnies KM, Realubit R, Karan C, Rand JH, Tatonetti NP. A novel, rapid method to compare the therapeutic windows of oral anticoagulants using the Hill coefficient. Sci Rep. 2016 Jul 21;6:29387.

Woo JH, Shimoni Y, Yang WS, Subramaniam P, Iyer A, Nicoletti P, Rodríguez Martínez M, López G, Mattioli M, Realubit R, Karan C, Stockwell BR, Bansal M, Califano A. Elucidating compound mechanism of action by network perturbation analysis. Cell. 2015 Jul 16;162(2):441-51. 

Jain S, Jirau-Serrano X, Zullo KM, Scotto L, Palermo CF, Sastra SA, Olive KP, Cremers S, Thomas T, Wei Y, Zhang Y, Bhagat G, Amengual JE, Deng C, Karan C, Realubit R, Bates SE, O'Connor OA. Preclinical pharmacologic evaluation of pralatrexate and romidepsin confirms potent synergy of the combination in a murine model of human T-cell lymphoma. Clin Cancer Res. 2015 May 1;21(9):2096-106.

Bansal M, Yang J, Karan C, Menden MP, Costello JC, Tang H, Xiao G, Li Y, Allen J, Zhong R, Chen B, Kim M, Wang T, Heiser LM, Realubit R, Mattioli M, Alvarez MJ, Shen Y; NCI-DREAM Community, Gallahan D, Singer D, Saez-Rodriguez J, Xie Y, Stolovitzky G, Califano A; NCI-DREAM Community. A community computational challenge to predict the activity of pairs of compounds. Nat Biotechnol. 2014 Dec;32(12):1213-22. 

Sonabend AM, Carminucci AS, Amendolara B, Bansal M, Leung R, Lei L, Realubit R, Li H, Karan C, Yun J, Showers C, Rothcock R, O J, Califano A, Canoll P, Bruce JN. Convection-enhanced delivery of etoposide is effective against murine proneural glioblastoma. Neuro Oncol. 2014 Sep;16(9):1210-9.

Gold B, Pingle M, Brickner SJ, Shah N, Roberts J, Rundell M, Bracken WC, Warrier T, Somersan S, Venugopal A, Darby C, Jiang X, Warren JD, Fernandez J, Ouerfelli O, Nuermberger EL, Cunningham-Bussel A, Rath P, Chidawanyika T, Deng H, Realubit R, Glickman JF, Nathan CF. Nonsteroidal anti-inflammatory drug sensitizes Mycobacterium tuberculosis to endogenous and exogenous antimicrobials. Proc Natl Acad Sci U S A. 2012 Oct 2;109(40):16004-11.

Porotto M, Orefice G, Yokoyama CC, Mungall BA, Realubit R, Sganga ML, Aljofan M, Whitt M, Glickman F, Moscona A. Simulating henipavirus multicycle replication in a screening assay leads to identification of a promising candidate for therapy. J Virol. 2009 May;83(10):5148-55.

 


Address


Lab Staff